FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2995315593> ?p ?o ?g. }

• W2995315593 endingPage "1079" @default.
• W2995315593 startingPage "1070" @default.
• W2995315593 abstract "Abstract Objective To examine the impact on quality of life (QOL) of patients with hATTR amyloidosis with polyneuropathy treated with inotersen (Tegsedi™) versus placebo. Methods Data were from the NEURO-TTR trial (ClinicalTrials.gov Identifier: NCT01737398), a phase 3, multinational, randomized, double-blind, placebo-controlled study of inotersen in patients with hATTR amyloidosis with polyneuropathy. At baseline and week 66, QOL measures—the Norfolk-QOL-Diabetic Neuropathy (DN) questionnaire and SF-36v2 ® Health Survey (SF-36v2)—were assessed. Treatment differences in mean changes in QOL from baseline to week 66 were tested using mixed-effect models with repeated measures. Responder analyses compared the percentages of patients whose QOL meaningfully improved or worsened from baseline to week 66 in inotersen and placebo arms. Descriptive analysis of item responses examined treatment differences in specific activities and functions at week 66. Results Statistically significant mean differences between treatment arms were observed for three of five Norfolk-QOL-DN domains and five of eight SF-36v2 domains, with better outcomes for inotersen than placebo in physical functioning, activities of daily living, neuropathic symptoms, pain, role limitations due to health problems, and social functioning. A larger percentage of patients in the inotersen arm than the placebo arm showed preservation or improvement in Norfolk-QOL-DN and SF-36v2 scores from baseline to week 66. Responses at week 66 showed more substantial problems with daily activities and functioning for patients in the placebo arm than in the inotersen arm. Conclusion Patients with hATTR amyloidosis with polyneuropathy treated with inotersen showed preserved or improved QOL at 66 weeks compared to those who received placebo." @default.
• W2995315593 created "2019-12-26" @default.
• W2995315593 creator A5002248011 @default.
• W2995315593 creator A5003963209 @default.
• W2995315593 creator A5007252463 @default.
• W2995315593 creator A5008109491 @default.
• W2995315593 creator A5009122387 @default.
• W2995315593 creator A5015330548 @default.
• W2995315593 creator A5029639314 @default.
• W2995315593 creator A5043229467 @default.
• W2995315593 creator A5044877787 @default.
• W2995315593 creator A5049653276 @default.
• W2995315593 creator A5055800393 @default.
• W2995315593 creator A5056200724 @default.
• W2995315593 creator A5064165672 @default.
• W2995315593 creator A5065854605 @default.
• W2995315593 creator A5072181166 @default.
• W2995315593 creator A5074880309 @default.
• W2995315593 creator A5080622202 @default.
• W2995315593 creator A5082591664 @default.
• W2995315593 creator A5085821633 @default.
• W2995315593 creator A5089060660 @default.
• W2995315593 creator A5090182780 @default.
• W2995315593 creator A5091001804 @default.
• W2995315593 date "2019-12-18" @default.
• W2995315593 modified "2023-09-26" @default.
• W2995315593 title "Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis" @default.
• W2995315593 cites W1583848026 @default.
• W2995315593 cites W1705652151 @default.
• W2995315593 cites W1977733462 @default.
• W2995315593 cites W1980144587 @default.
• W2995315593 cites W1988429877 @default.
• W2995315593 cites W1991876073 @default.
• W2995315593 cites W1996927016 @default.
• W2995315593 cites W2011246655 @default.
• W2995315593 cites W2018281939 @default.
• W2995315593 cites W2042252958 @default.
• W2995315593 cites W2078522982 @default.
• W2995315593 cites W2080914865 @default.
• W2995315593 cites W2118369819 @default.
• W2995315593 cites W2148373528 @default.
• W2995315593 cites W2160966221 @default.
• W2995315593 cites W2188931003 @default.
• W2995315593 cites W2212415077 @default.
• W2995315593 cites W2264916680 @default.
• W2995315593 cites W2495787001 @default.
• W2995315593 cites W2706854482 @default.
• W2995315593 cites W2739898475 @default.
• W2995315593 cites W2796779108 @default.
• W2995315593 cites W2809989268 @default.
• W2995315593 cites W2810909862 @default.
• W2995315593 cites W2887352853 @default.
• W2995315593 doi "https://doi.org/10.1007/s00415-019-09671-9" @default.
• W2995315593 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7109169" @default.
• W2995315593 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31853709" @default.
• W2995315593 hasPublicationYear "2019" @default.
• W2995315593 type Work @default.
• W2995315593 sameAs 2995315593 @default.
• W2995315593 citedByCount "19" @default.
• W2995315593 countsByYear W29953155932020 @default.
• W2995315593 countsByYear W29953155932021 @default.
• W2995315593 countsByYear W29953155932022 @default.
• W2995315593 countsByYear W29953155932023 @default.
• W2995315593 crossrefType "journal-article" @default.
• W2995315593 hasAuthorship W2995315593A5002248011 @default.
• W2995315593 hasAuthorship W2995315593A5003963209 @default.
• W2995315593 hasAuthorship W2995315593A5007252463 @default.
• W2995315593 hasAuthorship W2995315593A5008109491 @default.
• W2995315593 hasAuthorship W2995315593A5009122387 @default.
• W2995315593 hasAuthorship W2995315593A5015330548 @default.
• W2995315593 hasAuthorship W2995315593A5029639314 @default.
• W2995315593 hasAuthorship W2995315593A5043229467 @default.
• W2995315593 hasAuthorship W2995315593A5044877787 @default.
• W2995315593 hasAuthorship W2995315593A5049653276 @default.
• W2995315593 hasAuthorship W2995315593A5055800393 @default.
• W2995315593 hasAuthorship W2995315593A5056200724 @default.
• W2995315593 hasAuthorship W2995315593A5064165672 @default.
• W2995315593 hasAuthorship W2995315593A5065854605 @default.
• W2995315593 hasAuthorship W2995315593A5072181166 @default.
• W2995315593 hasAuthorship W2995315593A5074880309 @default.
• W2995315593 hasAuthorship W2995315593A5080622202 @default.
• W2995315593 hasAuthorship W2995315593A5082591664 @default.
• W2995315593 hasAuthorship W2995315593A5085821633 @default.
• W2995315593 hasAuthorship W2995315593A5089060660 @default.
• W2995315593 hasAuthorship W2995315593A5090182780 @default.
• W2995315593 hasAuthorship W2995315593A5091001804 @default.
• W2995315593 hasBestOaLocation W29953155931 @default.
• W2995315593 hasConcept C126322002 @default.
• W2995315593 hasConcept C142724271 @default.
• W2995315593 hasConcept C159110408 @default.
• W2995315593 hasConcept C1862650 @default.
• W2995315593 hasConcept C204787440 @default.
• W2995315593 hasConcept C27081682 @default.
• W2995315593 hasConcept C2775892965 @default.
• W2995315593 hasConcept C2779951007 @default.
• W2995315593 hasConcept C2779951463 @default.
• W2995315593 hasConcept C71924100 @default.
• W2995315593 hasConcept C79544238 @default.

• next